Efficacy of insulin analogues in diabetic patients attending primary care centers

References

1. ↵
   1. Whiting DR,
   2. Guariguata L,
   3. Weil C,
   4. Shaw J

   (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321.

   OpenUrlCrossRefPubMed
2. ↵
   1. Almutairi N,
   2. Alkharfy KM

   (2013) Direct medical cost and glycemic control in type 2 diabetic Saudi patients. Appl Health Econ Health Policy 11:671–675.

   OpenUrl
3. ↵
   1. American Diabetes Association

   (2012) Standards of medical care in diabetes--2012. Diabetes Care 35(Suppl 1):S11–S63.

   OpenUrlFREE Full Text
4. ↵
   1. Albers JW,
   2. Herman WH,
   3. Pop-Busui R,
   4. Feldman EL,
   5. Martin CL,
   6. Cleary PA,
   7. et al.

   (2010) Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33:1090–1096.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Horvath K,
   2. Jeitler K,
   3. Berghold A,
   4. Ebrahim SH,
   5. Gratzer TW,
   6. Plank J,
   7. et al.

   (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2):CD005613.
6. ↵
   1. Singh SR,
   2. Ahmad F,
   3. Lal A,
   4. Yu C,
   5. Bai Z,
   6. Bennett H

   (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Plank J,
   2. Siebenhofer A,
   3. Berghold A,
   4. Jeitler K,
   5. Horvath K,
   6. Mrak P,
   7. et al.

   (2005) Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 165:1337–1344.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Houlden R,
   2. Ross S,
   3. Harris S,
   4. Yale JF,
   5. Sauriol L,
   6. Gerstein HC

   (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 78:254–258.

   OpenUrlCrossRefPubMed
9. ↵
   1. Kesavadev J

   (2013) Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Indian J Endocrinol Metab 17(Suppl 2):S565–S568.

   OpenUrl
10. ↵
    1. Porcellati F,
    2. Bolli GB,
    3. Fanelli CG

    (2011) Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13(Suppl 1):S15–S24.

    OpenUrlPubMed
11. ↵
    1. Jansen HJ,
    2. Vervoort GM,
    3. de Haan AF,
    4. Netten PM,
    5. de Grauw WJ,
    6. Tack CJ

    (2014) Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study. Diabetes Care 37:2710–2717.

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. McCulloch DK,
    2. Glasgow RE,
    3. Hampson SE,
    4. Wagner E

    (1994) A systematic approach to diabetes management in the post-DCCT era. Diabetes Care 17:765–769.

    OpenUrlAbstract/FREE Full Text
13. ↵
    1. Rubin RR,
    2. Peyrot M

    (2004) Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 27:2495–2497.

    OpenUrlFREE Full Text
14. ↵
    1. Bierwirth RA,
    2. Kohlmann T,
    3. Moock J,
    4. Holle R,
    5. Landgraf W

    (2010) [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study]. Med Klin (Munich) 105:792–801, German.

    OpenUrlPubMed